Search - tctmd.com

Displaying 321 - 340 of 810

Sort: Relevancy | Date

No Survival Benefit With Revascularization in Stable CAD, Meta-analysis Confirms

News Conference News EuroPCR 2020

No Survival Benefit With Revascularization in Stable CAD, Meta-analysis Confirms

Michael O'Riordan

June 26, 2020

Most Stable Angina Patients Not Taking First-line Meds

News Daily News

Most Stable Angina Patients Not Taking First-line Meds

June 18, 2020

Possible Antithrombotic and Anti-inflammatory Therapies for COVID-19

News Daily News

Possible Antithrombotic and Anti-inflammatory Therapies for COVID-19

Michael O'Riordan

June 08, 2020

Risk of Dying Doubled in Wuhan COVID-19 Patients With Hypertension

News Daily News

Risk of Dying Doubled in Wuhan COVID-19 Patients With Hypertension

June 08, 2020

Women, Elderly, Minorities Vastly Underrepresented in Clinical Trials Over Decades

News Daily News

Women, Elderly, Minorities Vastly Underrepresented in Clinical Trials Over Decades

Yael L. Maxwell

May 28, 2020

No Worse COVID-19 Prognosis With ACE Inhibitors, ARBs: ‘Living’ Review Suggests

News Daily News

No Worse COVID-19 Prognosis With ACE Inhibitors, ARBs: ‘Living’ Review Suggests

Yael L. Maxwell

May 21, 2020

Coronary Calcium-Guided Statin Strategy Cost-effective in African-Americans

News Daily News

Coronary Calcium-Guided Statin Strategy Cost-effective in African-Americans

Michael O'Riordan

May 15, 2020

FOURIER Surveys Reassure About Cognitive Safety of Evolocumab

News Daily News

FOURIER Surveys Reassure About Cognitive Safety of Evolocumab

May 06, 2020

COVID-19, ACE Inhibitors, and ARBs: Multiple Studies Show No Increased Risk

News Daily News

COVID-19, ACE Inhibitors, and ARBs: Multiple Studies Show No Increased Risk

Michael O'Riordan

May 05, 2020

Alirocumab ‘Modestly’ Cost-effective at Lower List Price: ODYSSEY OUTCOMES

News Daily News

Alirocumab ‘Modestly’ Cost-effective at Lower List Price: ODYSSEY OUTCOMES

Michael O'Riordan

May 04, 2020

New Questions About Triple Therapy After PAD Revascularization: VOYAGER PAD Substudy

News Conference News ACC 2020

New Questions About Triple Therapy After PAD Revascularization: VOYAGER PAD Substudy

April 02, 2020

Icosapent Ethyl’s CV Benefit Closely Tied to Serum EPA Levels: REDUCE-IT

News Conference News ACC 2020

Icosapent Ethyl’s CV Benefit Closely Tied to Serum EPA Levels: REDUCE-IT

April 02, 2020

Pooled Inclisiran Data: Safe LDL-Lowering, Plus Hints of Fewer CVD Events

News Conference News ACC 2020

Pooled Inclisiran Data: Safe LDL-Lowering, Plus Hints of Fewer CVD Events

Michael O'Riordan

April 02, 2020

EPA Levels and Cardiovascular Outcomes in the Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial

Presentation ACC 2020

EPA Levels and Cardiovascular Outcomes in the Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial

Presenter: Deepak L. Bhatt

March 30, 2020

ISCHEMIA in Print: New MI Data and More Calls for Longer Follow-up

News Conference News ACC 2020

ISCHEMIA in Print: New MI Data and More Calls for Longer Follow-up

March 30, 2020

Diabetes May Boost Benefits of COMPASS Dual Antithrombotic Approach

News Conference News ACC 2020

Diabetes May Boost Benefits of COMPASS Dual Antithrombotic Approach

March 28, 2020

COMPASS Antithrombotic Approach Works Well in Prior-PCI Patients

News Daily News

COMPASS Antithrombotic Approach Works Well in Prior-PCI Patients

March 27, 2020

Cardiac Considerations Amid COVID-19: Shared Stories May Save Lives

News Daily News

Cardiac Considerations Amid COVID-19: Shared Stories May Save Lives

March 25, 2020

Missed Opportunities: Many HF Patients Not Tested for CAD

News Daily News

Missed Opportunities: Many HF Patients Not Tested for CAD

March 20, 2020

Type 2 MI Linked to More CV Deaths, Even in Younger Patients

News Daily News

Type 2 MI Linked to More CV Deaths, Even in Younger Patients

March 04, 2020

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.